OPKO narrows operating loss 88% as Nicoya equity stake, Labcorp earnout boost revenue 4.3%

Filed July 27, 2026 · Period ending June 30, 2026 · Compared to 10-Q Jul 31, 2025 · ~2 min read

Key Changes

• high

  Operating loss narrowed from $60.0M to $7.0M (88% improvement) as the company exited divested oncology operations, recognized a $29.4M Nicoya equity stake, and received an $18.4M Labcorp earnout.

  MD&A: Operating Results verify on EDGAR →
• high

  Amended Nicoya license agreement in April 2026 to expand licensed field and reduce future royalty rates in exchange for a 15% equity stake in Nicoya's parent, valued at $29.4M and recognized as Q2 revenue.

  Notes: Nicoya Amendment verify on EDGAR →
• high

  Received $18.4M earnout from Labcorp in Q2 2026, closing out contingent consideration from the September 2025 oncology asset sale; no further earnout expected.

  Notes: Labcorp Earnout verify on EDGAR →